[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd3-complex":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD3 Complex",12,8,[8,16,23,29,36,42,48,55,61,68,74,81],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07013565","Chemoimmunotherapy for ALK+ Relapsed\u002FRefractory ALCL",[12],"Phase 2","RECRUITING","2026-08-26T02:15:42.447052Z","2026-05-29T15:36:40.177956Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04220190","RAPA-501 Therapy for ALS",[20],"Phase 2\u002FPhase 3","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:28.869673Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05592015","Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia",[12],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.203289Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05432310","Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector",[33],"Phase 1\u002FPhase 2","2026-08-03T03:32:35.491916Z","2026-05-05T02:43:28.187025Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT03538899","Autologous Gene Therapy for Artemis-Deficient SCID",[33],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.477543Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",[12],"2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.721320Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT07332507","Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma",[52],"Phase 1","2026-08-26T02:16:35.654046Z","2026-07-19T19:36:05.138147Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04301076","Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)",[52],"2026-08-26T02:16:08.402952Z","2026-07-19T19:36:05.132850Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT07662928","Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-05T03:45:20.354557Z",{"nct_id":69,"title":70,"phases":71,"status":65,"updated_at":72,"content_modified":73},"NCT07682792","Golidocitinib in Patients With Mycosis Fungoides\u002FSézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia",[12],"2026-08-26T02:19:16.454910Z","2026-07-19T19:36:05.150066Z",{"nct_id":75,"title":76,"phases":77,"status":78,"updated_at":79,"content_modified":80},"NCT01186913","Natural History Study of SCID Disorders",[],"ENROLLING_BY_INVITATION","2026-08-26T02:17:20.511551Z","2026-06-16T05:54:07.954314Z",{"nct_id":82,"title":83,"phases":84,"status":85,"updated_at":86,"content_modified":87},"NCT05998408","JAK1\u002F2 Inhibitor Ruxolitinib for Relapsed\u002FRefractory Immune Bone Marrow Failure",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T02:04:34.624671Z","2026-05-05T02:35:31.872333Z"]